LP-003

Phase 3Biologic

LLongbio Pharma

LP-003 is one of 69 biologic programs targeting Chronic Rhinosinusitis With Nasal Polyps. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Rhinosinusitis With Nasal PolypsNot yet recruiting

Adult SubjectActive, not recruiting

Single DoseActive, not recruiting

Seasonal Allergic RhinitisActive, not recruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 2

Not yet recruiting

Adult SubjectPhase 1

Active, not recruiting

Single DosePhase 2

Active, not recruiting

Seasonal Allergic RhinitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Seasonal Allergic Rhinitis

#DrugCompanyPhaseTrials

Flovent

PParatek Pharmaceuticals Inc

Approved

7 2

Clarinex

OOrganon and Co

Approved

7 3

Allegra

CChattem

Approved

7 4

Zyrtec

KKenvue Brands

Approved

7 5

Claritin

PPerrigo Company

Approved

4 6

Singulair

OOrganon and Co

Approved

3 7

Asmanex Hfa

PPerrigo Company

Approved

3 8

Xyzal

CChattem

Approved

2 9

Kenalog

BBausch Health Americas, Inc.

Pulmicort

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Adult Subject

NCT06604949

Phase 3Active, not recruiting

Seasonal Allergic Rhinitis

NCT07291284

Q3 2027

Phase 2Not yet recruiting

Chronic Rhinosinusitis With Nasal Polyps

NCT07313917

Q3 2029

Phase 2Recruiting

Allergic Asthma

NCT07342803

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

Active, not recruiting·LLongbio Pharma·Phase 3·NCT07291284·546 enrolled

Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult

Completed·LLongbio Pharma·Phase 2·NCT06046391·180 enrolled

Adult1 trial

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Completed·LLongbio Pharma·Phase 1·NCT06294288·60 enrolled

Single Dose1 trial

A Study of Single Dose of LP-003 in Adolescent Subjects

Active, not recruiting·LLongbio Pharma·Phase 1/2·NCT07148557·6 enrolled

Adult Subject1 trial

A Study of Single Dose of LP-003 in Healthy Adult Subjects

Active, not recruiting·LLongbio Pharma·Phase 1·NCT06604949·12 enrolled

Allergic Asthma1 trial

Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

Recruiting·LLongbio Pharma·Phase 2·NCT07342803·200 enrolled

2 more indications

Chronic Rhinosinusitis With Nasal Polyps1 trial

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Not yet recruiting·LLongbio Pharma·Phase 2·NCT07313917·150 enrolled

Chronic Spontaneous Urticaria1 trial

Multi-center,Randomized,Double-blind Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Completed·LLongbio Pharma·Phase 2·NCT06228560·202 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for LP-003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LP-003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LP-003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Longbio Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: LLongbio Pharma

LP-003

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q3 2029

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

Adult1 trial

Single Dose1 trial

Adult Subject1 trial

Allergic Asthma1 trial

Chronic Rhinosinusitis With Nasal Polyps1 trial

Chronic Spontaneous Urticaria1 trial

References

Drug Info

Quick Facts

Related News